Somewhat Favorable News Coverage Somewhat Unlikely to Affect Neos Therapeutics (NASDAQ:NEOS) Share Price

Media headlines about Neos Therapeutics (NASDAQ:NEOS) have been trending somewhat positive on Friday, Accern Sentiment reports. Accern scores the sentiment of press coverage by analyzing more than 20 million news and blog sources. Accern ranks coverage of publicly-traded companies on a scale of negative one to one, with scores nearest to one being the most favorable. Neos Therapeutics earned a news sentiment score of 0.15 on Accern’s scale. Accern also assigned news headlines about the company an impact score of 46.4744585341217 out of 100, indicating that recent press coverage is somewhat unlikely to have an impact on the company’s share price in the next few days.

Shares of Neos Therapeutics (NASDAQ NEOS) traded down 0.75% during trading on Friday, reaching $6.65. 265,651 shares of the company traded hands. The company’s market capitalization is $186.73 million. The stock’s 50 day moving average is $6.90 and its 200 day moving average is $7.00. Neos Therapeutics has a 1-year low of $4.85 and a 1-year high of $9.60.

Neos Therapeutics (NASDAQ:NEOS) last issued its quarterly earnings data on Tuesday, August 8th. The company reported ($0.83) earnings per share for the quarter, meeting the Zacks’ consensus estimate of ($0.83). Neos Therapeutics had a negative return on equity of 611.78% and a negative net margin of 511.74%. The company had revenue of $4.91 million during the quarter. On average, analysts forecast that Neos Therapeutics will post ($3.20) EPS for the current year.

Several analysts have commented on the stock. Zacks Investment Research raised shares of Neos Therapeutics from a “hold” rating to a “buy” rating and set a $9.75 price target for the company in a research report on Saturday, June 3rd. Cantor Fitzgerald set a $20.00 price target on shares of Neos Therapeutics and gave the company a “buy” rating in a research report on Wednesday, August 9th. BMO Capital Markets reissued an “outperform” rating and set a $15.00 price target on shares of Neos Therapeutics in a research report on Tuesday, June 20th. Royal Bank Of Canada set a $12.00 price target on shares of Neos Therapeutics and gave the company an “outperform” rating in a research report on Tuesday, August 8th. Finally, ValuEngine raised shares of Neos Therapeutics from a “strong sell” rating to a “sell” rating in a research report on Tuesday, June 20th. One research analyst has rated the stock with a sell rating, two have issued a hold rating and four have given a buy rating to the company. The company presently has an average rating of “Hold” and a consensus target price of $14.00.

ILLEGAL ACTIVITY WARNING: “Somewhat Favorable News Coverage Somewhat Unlikely to Affect Neos Therapeutics (NASDAQ:NEOS) Share Price” was originally published by BNB Daily and is owned by of BNB Daily. If you are accessing this piece of content on another publication, it was stolen and republished in violation of US and international copyright and trademark laws. The correct version of this piece of content can be read at https://www.baseball-news-blog.com/2017/08/19/somewhat-favorable-media-coverage-somewhat-unlikely-to-impact-neos-therapeutics-nasdaqneos-share-price-updated.html.

Neos Therapeutics Company Profile

Neos Therapeutics, Inc is a pharmaceutical company. The Company is focused on developing, manufacturing and commercializing products utilizing its modified-release drug delivery technology platform. Its segment is engaged in the development, manufacturing and commercialization of pharmaceuticals. It has utilized its platform to develop its product for the treatment of attention deficit hyperactivity disorder (ADHD).

Insider Buying and Selling by Quarter for Neos Therapeutics (NASDAQ:NEOS)

Receive News & Ratings for Neos Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Neos Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply